Adiponectin in chronic heart failure: Influence of diabetes and genetic variants

European Journal of Clinical Investigation

Volumn 41, Issue 12, 2011, Pages 1330-1338

  Masson, Serge ^a   Gori, Francesca ^a   Latini, Roberto ^a   Milani, Valentina ^a   Flyvbjerg, Allan ^b   Frystyk, Jan ^b   Crociati, Luisa ^a   Pietri, Silvia ^a   Vago, Tarcisio ^c   Barlera, Simona ^a   Maggioni, Aldo P ^d   Tognoni, Gianni ^e   Tavazzi, Luigi ^f   Omland, Torbjørn ^g   Franzosi, Maria Grazia ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF MILAN   (Italy)

^d ANMCO RESEARCH CENTER   (Italy)

^e Consorzio Mario Negri Sud ^*  (Italy)

^f GVM Hospitals of Care and Research   (Italy)

^g AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Adiponectin; Chronic heart failure; Clinical trial; Diabetes; Prognosis; Single nucleotide polymorphism

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ALLELE; ARTICLE; BODY MASS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENETIC VARIABILITY; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADIPONECTIN; AGE FACTORS; AGED; AGED, 80 AND OVER; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 81355149888     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02548.x     Document Type: Article

References (35)

1. Krenning G, Moonen JR, Harmsen MC. Pleiotropism of adiponectin: inflammation, neovascularization, and fibrosis. Circ Res 2009;104:1029-31.
2. Goldstein BJ, Scalia RG, Ma XL. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med 2009;6:27-35.
3. Fujioka D, Kawabata K, Saito Y, Kobayashi T, Nakamura T, Kodama Y et al. Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. Am J Physiol Heart Circ Physiol 2006;290:H2409-16.
4. Unno K, Shibata R, Izawa H, Hirashiki A, Murase Y, Yamada T et al. Adiponectin acts as a positive indicator of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy. Heart 2010;96:357-61.
5. Madsen EL, Rissanen A, Bruun JM, Skogstrand K, Tonstad S, Hougaard DM et al. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 2008;158:179-87.
6. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008;14:741-51.
7. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009;302:179-88.
8. Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C. Adiponectin: from obesity to cardiovascular disease. Obes Rev 2009;10:269-79.
9. Heid IM, Wagner SA, Gohlke H, Stefanadis C. Genetic architecture of the APM1 gene and its influence on adiponectin plasma levels and parameters of the metabolic syndrome in 1, 727 healthy Caucasians. Diabetes 2006;55:375-84.
10. Ling H, Waterworth DM, Stirnadel HA, Pollin TI, Barter PJ, Kesäniemi YA et al. Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study. Obesity (Silver Spring) 2009;17:737-44.
11. Heid IM, Henneman P, Hicks A, Coassin S, Winkler T, Aulchenko YS et al. Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals. Atherosclerosis 2010;208:412-20.
12. Menzaghi C, Trischitta V, Doria A. Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes 2007;56:1198-209.
13. Gu HF. Biomarkers of adiponectin: plasma protein variation and genomic DNA polymorphisms. Biomark Insights 2009;4:123-33.
14. Ingelsson E, Risérus U, Berne C, Frystyk J, Flyvbjerg A, Axelsson T et al. Adiponectin and risk of congestive heart failure. JAMA 2006;295:1772-4.
15. Frankel DS, Vasan RS, D'Agostino RB Sr, Benjamin EJ, Levy D, Wang TJ et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 2009;53:754-62.
16. Van Berendoncks AM, Garnier A, Beckers P, Hoymans VY, Possemiers N, Fortin D et al. Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure. Circ Heart Fail 2010;3:185-94.
17. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756-62.
18. George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006;92:1420-4.
19. McEntegart MB, Awede B, Petrie MC, Sattar N, Dunn FG, MacFarlane NG et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 2007;28:829-35.
20. GISSI-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1223-30.
21. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
22. Andersen KK, Frystyk J, Wolthers OD, Heuck C, Flyvbjerg A. Gender differences of oligomers and total adiponectin during puberty: a cross-sectional study of 859 Danish school children. J Clin Endocrinol Metab 2007;92:1857-62.
23. Di Stasi D, Bernasconi R, Marchioli R, Marfisi RM, Rossi G, Tognoni G et al. Early modifications of fatty acid composition in plasma phospholipids, platelets and mononucleates of healthy volunteers after low doses of n-3 polyunsaturated fatty acids. Eur J Clin Pharmacol 2004;60:183-90.
24. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72.
25. Tsutamoto T, Tanaka T, Sakai H, Ishikawa C, Fujii M, Yamamoto T et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 2007;28:1723-30.
26. Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 2007;167:1510-7.
27. Tishinsky JM, Ma DW, Robinson LE. Eicosapentaenoic acid and rosiglitazone increase adiponectin in an additive and PPARgamma-dependent manner in human adipocytes. Obesity (Silver Spring) 2011;19:262-8.
28. Banga A, Unal R, Tripathi P, Pokrovskaya I, Owens RJ, Kern PA et al. Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab. 2009;296:E480-849.
29. Takano H, Obata JE, Kodama Y, Kitta Y, Nakamura T, Mende A et al. Adiponectin is released from the heart in patients with heart failure. Int J Cardiol 2009;132:221-6.
30. Wang Y, Lau WB, Gao E, Tao L, Yuan Y, Li R et al. Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury. Am J Physiol Endocrinol Metab 2010;298:E663-70.
31. Tanaka T, Tsutamoto T, Sakai H, Nishiyama K, Fujii M, Yamamoto T et al. Effect of atrial natriuretic peptide on adiponectin in patients with heart failure. Eur J Heart Fail 2008;10:360-6.
32. Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009;53:2070-7.
33. Springer J, Anker SD, Doehner W. Adiponectin resistance in heart failure and the emerging pattern of metabolic failure in chronic heart failure. Circ Heart Fail 2010;3:181-2.
34. Kyriakou T, Collins LJ, Spencer-Jones NJ, Malcolm C, Wang X, Snieder H et al. Adiponectin gene ADIPOQ SNP associations with serum adiponectin in two female populations and effects of SNPs on promoter activity. J Hum Genet 2008;53:718-27.
35. Menzaghi C, Salvemini L, Paroni G, De Bonis C, Mangiacotti D, Fini G et al. Circulating high molecular weight adiponectin isoform is heritable and shares a common genetic background with insulin resistance in nondiabetic White Caucasians from Italy: evidence from a family-based study. J Intern Med 2010;267:287-94.